Skip to main content
. 2020 Mar 16;25(6):e900–e908. doi: 10.1634/theoncologist.2019-0729

Figure 2.

Figure 2

Treatment algorithm for premenopausal women with hormone receptor–positive/human epidermal growth receptor 2–negative mBC 21, 39, 40. *In patients with PIK3CA mutations as detected by a U.S. Food and Drug Administration–approved test. †In patients with germline BRCA1/2 mutations. ‡If not received in first line.Abbreviations: CDK4/6i, cyclin‐dependent kinase 4/6 inhibitor (palbociclib, ribociclib, abemaciclib); ET, endocrine therapy; mTORi, mammalian target of rapamycin inhibitor (everolimus); NSAI, nonsteroidal reversible aromatase inhibitor (anastrozole, letrozole); PARPi, poly ADP ribose polymerase inhibitor (olaparib, talazoparib); PI3Ki, phosphatidylinositol‐3‐kinase inhibitor (alpelisib); SAI, steroidal irreversible aromatase inactivator (exemestane); SERD, selective estrogen receptor degrader (fulvestrant); SERM, selective estrogen receptor modulator (tamoxifen, toremifene).